Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00359684 · ClinicalTrials.gov registry record
Use of Cysteamine in the Treatment of Cystinosis
A clinical trial of Cystinosis, sponsored by National Human Genome Research Institute (NHGRI).
- Recruiting
- Registry status
- 330
- Enrollment target
- 1
- Study location
NCT00359684 is a study of Cystinosis that is actively recruiting participants, run by National Human Genome Research Institute (NHGRI). The registered enrollment target is 330 participants, above the 122-participant average among 4 other Cystinosis trials with a reported enrollment target (170% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00359684, a study of Cystinosis, is actively recruiting participants, sponsored by National Human Genome Research Institute (NHGRI).
- RECRUITING
- Registry status
- 330 participants
- Enrollment target
- 1
- Study location
Study Summary
Cystinosis is an inherited disease resulting in poor growth and kidney failure. There is no known cure for cystinosis, although kidney transplantation may help the renal failure and prolong survival. Both the kidney damage and growth failure are thought to be due to the accumulation of the amino acid cystine within the cells of the body. The cystine storage later damages other organs besides the kidneys, including the thyroid gland, pancreas, eyes, and muscle. The drug cysteamine (Cystagon; ProCysBi) is an oral medication given to patients with cystinosis prior to kidney transplantation. The drug works by reducing the level of cystine in the white blood cells and muscle tissue. The drug may also decrease levels of cystine in the kidneys and other tissues. This study has several goals: 1. Long-term surveillance of cysteamine treated patients. 2. Detection of new non-kidney complications of cystinosis. 3. Maintenance of a patient population for genetic testing (mutational analysis) of the cystinosis gene.\<TAB\> ...
Conditions Studied
Interventions
- DRUG Cysteamine
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 330 participants |
| Start Date | 1979-01-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00359684
The ClinicalTrials.gov registry entry for NCT00359684 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 330 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 122-participant average among 4 other Cystinosis trials with a reported enrollment target (170% higher). The listed sponsor is National Human Genome Research Institute (NHGRI), which has 185 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cystinosis appearing as the primary indexed condition, and to 1 intervention - of which Cysteamine is the first listed.
NCT00359684 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00359684 about?
NCT00359684 is a clinical study titled "Use of Cysteamine in the Treatment of Cystinosis". Cystinosis is an inherited disease resulting in poor growth and kidney failure. There is no known cure for cystinosis, although kidney transplantation may help the renal failure and prolong survival. Both the kidney damage and growth failure are thought to be due to the accumulation of the amino aci...
What is the current status of trial NCT00359684?
This trial is currently recruiting. The enrollment target is 330 participants. The study started on 1979-01-04.
What conditions does trial NCT00359684 study?
This clinical trial studies the following conditions: Cystinosis.
What interventions are being tested in trial NCT00359684?
The interventions under investigation include: Cysteamine (DRUG).
Who is sponsoring clinical trial NCT00359684?
This trial is sponsored by National Human Genome Research Institute (NHGRI), which has 185 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00359684 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cystinosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor
RECRUITING · Phase 1
-
Establishment of a Database for Long-Term Monitoring of Patients With Nephropathic Cystinosis
COMPLETED
-
Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103)
COMPLETED · Phase 3
-
Safety/Effectiveness Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Cysteamine Treatment Naive Patients With Cystinosis
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.